- Home
- CNTA vs DAN Comparison
CNTA vs DAN Comparison
Compare CNTA & DAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTA | DAN |
|---|---|---|
| Founded | 2020 | 1904 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 3.3B |
| IPO Year | 2021 | 1998 |
Fundamental Metrics
Financial Performance| Metric | CNTA | DAN |
|---|---|---|
| Price | $39.56 | $35.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $42.00 | $37.20 |
| AVG Volume (30 Days) | ★ 4.6M | 974.3K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | 29.13 | ★ 264.10 |
| EPS | N/A | ★ 0.64 |
| Revenue | $15,000,000.00 | ★ $7,500,000,000.00 |
| Revenue This Year | N/A | $1.77 |
| Revenue Next Year | N/A | $4.02 |
| P/E Ratio | ★ N/A | $55.13 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.95 | $11.06 |
| 52 Week High | $40.26 | $36.95 |
Technical Indicators
Market Signals| Indicator | CNTA | DAN |
|---|---|---|
| Relative Strength Index (RSI) | 75.69 | 58.32 |
| Support Level | $24.80 | $18.71 |
| Resistance Level | $40.26 | $36.28 |
| Average True Range (ATR) | 0.50 | 1.03 |
| MACD | 0.14 | 0.19 |
| Stochastic Oscillator | 94.78 | 71.36 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
About DAN Dana Incorporated
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.